Kura Oncology, Inc. (KURA) Discusses KO-7246 Data and Development Strategy for Menin Inhibitors in Diabetes - Slideshow

Kura Oncology, Inc. (KURA) presented data on its menin inhibitor KO-7246 at the American Diabetes Association's 82nd Scientific Sessions. The drug showed promising results in reducing blood sugar levels and improving insulin sensitivity in preclinical models. Kura Oncology is planning to advance KO-7246 into clinical trials.